GlassScriptPhysician profile
Larry S Pierce
NPI 1689987042
$3,353.44
in general payments reported to CMS, 2019-2025
35 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $345 · 2023: $490 · 2024: $889 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $734.39 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $607.74 | 2021-2025 | |
| Novo Nordisk INC | $489.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $167.65 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Alkermes, INC. | $118.80 | 2025 | Aristada, Lybalvi |
| Pfizer INC. | $113.71 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.23 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $100.12 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.27 | 2021-2025 | Jardiance |
| Lundbeck LLC | $83.16 | 2025 | Rexulti |
| Hydrofera LLC | $77.80 | 2022-2024 | Hydrofera Blue |
| Amgen INC. | $63.63 | 2022-2025 | Repatha, Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $54.33 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $53.65 | 2025 | Trintellix |
| Abbott Laboratories | $51.08 | 2023 | Freestyle Libre 2 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $46.39 | 2024 | |
| Mimedx Group, INC. | $45.67 | 2024-2025 | |
| Neurelis, INC. | $33.89 | 2024 | Valtoco |
| Coloplast Corp | $33.81 | 2024 | |
| Merck Sharp & Dohme LLC | $28.81 | 2025 | Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $23.11 | 2022 | |
| Glaxosmithkline, LLC. | $22.13 | 2025 | Trelegy Ellipta |
| Molnlycke Health Care US, LLC | $19.86 | 2024 | Mepilex Border Sacrum, Mepilex Border Post-Op, Exufiber Ag+ |
| Bayer Healthcare Pharmaceuticals INC. | $18.54 | 2024 | |
| Seqirus USA INC | $18.34 | 2024 | Fluad, Flucelvax |
| Janssen Pharmaceuticals, INC | $18.15 | 2025 | Spravato |
| Beta Bionics, INC. | $16.16 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Paratek Pharmaceuticals, INC. | $16.07 | 2025 | Nuzyra |
| Boston Scientific Corporation | $15.55 | 2025 | Accolade Sr |
| Smith+Nephew, INC. | $15.32 | 2024 | Collagenase Santyl |
| Tactile Systems Technology INC | $14.89 | 2021 | |
| Currax Pharmaceuticals LLC | $14.37 | 2025 | Contrave |
| Kowa Pharmaceuticals America, INC. | $14.23 | 2025 | Zoryve |
| Corcept Therapeutics | $14.01 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $13.88 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.